ATF4 and hepatocellular carcinoma: As revealed by our experiments with hepatoma cells exposed to bortezomib along with nelfinavir or salubrinal, an overactivation of the eIF2α–ATF4 pathway perturbs other UPR branches and accelerates cell death.